Full-Time

Principal Scientist

Translational Sciences

Confirmed live in the last 24 hours

Arcellx

Arcellx

51-200 employees

Develops immunotherapies for cell therapy

Biotechnology
Healthcare

Compensation Overview

$160k - $175kAnnually

+ Bonus + Equity Grant

Senior

North Bethesda, MD, USA

Relocation assistance is offered if required.

Category
Genomics
Biology Lab & Research
Biology & Biotech
Requirements
  • PhD, MD or MD/PhD degree in a relevant scientific field (e.g., cancer biology, immunology, hematology), with 8+ years post-degree experience, inclusive of 3+ years of experience in a formalized Translational Science/Medicine role within a large pharma/biotech company is required.
  • Understanding of early or late-stage drug and translational development process, including clinical trial experience in industry or academia.
  • In-depth understanding of myeloid disease biology (e.g., AML, MDS), knowledge of clinical landscape, evolving therapy, and competitive scenarios.
  • Demonstrated record of research accomplishment as evidenced by publications or major contributions to drug development milestones.
  • Highly developed problem solving and risk management abilities.
  • Strategic thinker with proven leadership skills and/or prior project team leadership roles.
  • Proficiency in distilling complex issues and clearly articulating viable paths forward.
Responsibilities
  • Lead implementation of clinical biomarker strategy to enable target engagement characterization, PK/PD indication of biologic activity and assessment of patient response.
  • Serve as a key contributor to integrate, influence, and execute on translational/biomarker plans.
  • Communicate translational updates and conduct strategic discussions for key programs with diverse audiences, including senior management.
  • Understand key cancer pathway interactions and feedback mechanisms in clinical samples to inform ongoing clinical trials.
  • Define novel mechanisms of resistance by studying samples at relapse.
  • Contribute relevant scientific expertise, strategy, and experimentally-derived insights as a member of multidisciplinary project teams working to drive the preclinical to clinical translation of pipeline assets.
  • Plan, design, and execute IND-enabling pharmacology, pharmacokinetic and toxicology studies by applying knowledge of disease-associated pathways, preclinical models, and drug development.
  • Contribute to the preparation of IND applications and other regulatory documents, as appropriate, leveraging up-to-date knowledge of FDA cellular therapy guidance.
  • Establish and cultivate relationships with external CRO collaborators for basic and translational research.
  • Maintain a current and comprehensive understanding of disease biology, treatment paradigm, and competitive landscape for key programs.

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on harnessing the body's immune system to fight illnesses. The company conducts research and clinical trials to create safe and effective treatments, which are then commercialized through partnerships and licensing agreements. Unlike many competitors, Arcellx emphasizes proprietary technology in its approach to cell therapy. The goal is to meet unmet medical needs by providing advanced treatment options for patients.

Company Stage

IPO

Total Funding

$194.5M

Headquarters

Gaithersburg, Maryland

Founded

2014

Growth & Insights
Headcount

6 month growth

16%

1 year growth

25%

2 year growth

66%
Simplify Jobs

Simplify's Take

What believers are saying

  • Partnership with Kite expands development and commercialization opportunities for anito-cel.
  • Robust long-term responses observed in CART-ddBCMA Phase 1 expansion trial.
  • Increasing interest in CAR-T therapies beyond oncology broadens market potential.

What critics are saying

  • Competition from established CAR-T therapies like Abecma and Carvykti may limit market share.
  • Dependency on Gilead's Kite partnership could pose risks if dynamics change.
  • Potential delays in Phase 3 iMMagine-3 trial could impact market entry timeline.

What makes Arcellx unique

  • Arcellx's CART-ddBCMA has FDA Fast Track, Orphan Drug, and RMAT designations.
  • The novel D-Domain binder in anito-cel enhances antigen binding and cell killing.
  • ARC-SparX offers dosable and controllable CAR-T therapy options for multiple diseases.

Help us improve and share your feedback! Did you find this helpful?